Literature DB >> 16437537

In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered.

Mikko Airavaara1, Jelena Mijatovic, Tanja Vihavainen, Timo Petteri Piepponen, Mart Saarma, Liisa Ahtee.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) regulates striatal dopaminergic neurons. To study whether reduced endogenous GDNF affect morphine's effects on striatal dopamine transmission, we estimated extracellular concentrations of dopamine and its metabolites by microdialysis in vivo and tissue concentrations post mortem in mice lacking one GDNF allele (GDNF+/- mice). In the wild-type mice, acute morphine (5 and 10 mg/kg s.c.) increased accumbal dopamine output dose-dependently (maximally by 30 and 80%, respectively). In the GDNF+/- mice, 5 mg/kg of morphine enhanced the accumbal dopamine output maximally by 110%, and significantly more than morphine 10 mg/kg (maximally by 60%). Also, the response of extracellular accumbal DOPAC to acute morphine was significantly altered in the GDNF+/- mice. In mice of both genotypes, the responses to morphine in the caudate putamen were similar to but much less intense than those in the nucleus accumbens. Morphine at the doses 5, 10, and 30 mg/kg dose-dependently elevated the striatal tissue concentrations of DOPAC and HVA, but the effect of 30 mg/kg was significantly smaller in the GDNF+/- mice than in their wild-type littermates. The binding of [(3)H]DAMGO to striatal membrane homogenates was similar between the genotypes. However, morphine induced antinociception in the GDNF+/- mice at a smaller dose than in the controls. The finding that reduced GDNF level alters the effects of morphine on striatal dopamine and our previous findings of elevated extracellular striatal dopamine concentrations and FosB/DeltaFosB expression in the GDNF+/- mice show the importance of GDNF in the regulation of striatal dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16437537     DOI: 10.1002/syn.20245

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  25 in total

1.  Impaired striatal dopamine output of homozygous Wfs1 mutant mice in response to [K+] challenge.

Authors:  Vallo Matto; Anton Terasmaa; Eero Vasar; Sulev Kõks
Journal:  J Physiol Biochem       Date:  2010-10-23       Impact factor: 4.158

2.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

Review 3.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

4.  Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.

Authors:  Giuseppa Mudò; Johanna Mäkelä; Valentina Di Liberto; Timofey V Tselykh; Melania Olivieri; Petteri Piepponen; Ove Eriksson; Annika Mälkiä; Alessandra Bonomo; Minna Kairisalo; Jose A Aguirre; Laura Korhonen; Natale Belluardo; Dan Lindholm
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

5.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

6.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

7.  Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice.

Authors:  M Käenmäki; A Tammimäki; J A Garcia-Horsman; T Myöhänen; N Schendzielorz; M Karayiorgou; J A Gogos; P T Männistö
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

8.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

Review 9.  GDNF--a potential target to treat addiction.

Authors:  Sebastien Carnicella; Dorit Ron
Journal:  Pharmacol Ther       Date:  2008-12-24       Impact factor: 12.310

Review 10.  Why is neuroimmunopharmacology crucial for the future of addiction research?

Authors:  Mark R Hutchinson; Linda R Watkins
Journal:  Neuropharmacology       Date:  2013-06-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.